Enveric Biosciences, Inc.
ENVB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000890821
No open-market purchases or sales by Enveric Biosciences, Inc. insiders were filed in the last 90 days; 24 institutions reported holding it in 13F filings for Q2 2026, worth $736.8K in total; no superinvestor holds it.
Q4 2025 vs. Q3 2025
How the institutions holding Enveric Biosciences, Inc. changed between Q3 2025 and Q4 2025.
All holders in Q4 2025All holders in Q3 2025
| Measure | Q3 2025 | Q4 2025 | Change |
|---|---|---|---|
| Holders | 11 | 11 | 0 |
| Shares | 363.8K | 24.2K | −339.7K (−93.4%) |
| Value | $232.6K | $87.7K | −$144.9K (−62.3%) |
New holders (2)
Institutions that held Enveric Biosciences, Inc. at the end of Q4 2025 but not at the end of Q3 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Citigroup Inc | 2,276 | $8.26K | 0.00% |
| Danske Bank A/S | 1 | $4 | 0.00% |
Sold out (2)
Institutions that held Enveric Biosciences, Inc. at the end of Q3 2025 and filed for Q4 2025 without it.
| Institution | Shares, Q3 2025 | Value, Q3 2025 |
|---|---|---|
| Geode Capital Management, LLC | 28,510 | $18.2K |
| Citadel Advisors LLC | 22,674 | $14.5K |